Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

MenB to be added to national childhood immunisation programme

  • Comment

A vaccine against meningitis B will be available to all babies in the UK after the government agreed a deal with drug manufacturers.

The vaccine, which prevents meningitis caused by meningococcal group B (MenB) bacteria, will be added to the national childhood immunisation programme and is expected to be rolled out from the autumn.

Last year the government’s independent vaccine experts, the Joint Committee on Vaccination and Immunisation (JCVI), found evidence that Bexsero was effective in preventing MenB in infants.

“We will be the first country in the world to have a nationwide MenB vaccination programme”

Jeremy Hunt

However, the committee said at the time that routine child vaccination on the NHS would not be a cost-effective use of the health service’s resources.

Following negotiations, the government has now agreed a price with manufacturer GlaxoSmithKline for Bexsero, which is currently the only licensed MenB vaccination.

Children will receive the vaccine from when they are two months old, followed by another at four months and a booster at 12 months.

The JCVI has also advised that when the programme starts there should be a one-off, catch-up programme for babies aged three and four months of age.

The Department of Health said it expected the vaccine to be available for children from September.

Health secretary Jeremy Hunt said the deal meant the UK would be the first country to have a nationwide MenB vaccination programme.

“MenB can be severely disabling or fatal, especially in babies and young children. Losing a child is every parent’s worst nightmare, so I am delighted that we have reached an agreement with GSK to supply the vaccine,” he said.

“The new meningitis B vaccine for babies will reduce the number of cases in early childhood and ease the burden of the disease for the NHS”

Andrew Pollard

“I am very proud that we will be the first country in the world to have a nationwide MenB vaccination programme, helping to protect our children from a devastating disease,” added Mr Hunt.

Professor Andrew Pollard, chair of the JCVI, said: “[The committee] anticipates that introduction of the new meningitis B vaccine for babies will reduce the number of cases in early childhood, ease the burden of the disease for the NHS and defend the health of the nation’s children.”

Around 1,200 people, mainly babies and children, get meningitis caused by the meningococcal group B bacteria each year in the UK, with around one in 10 dying from the infection.

Meningitis charities welcomed the announcement. Chris Head, chief executive of Meningitis Research Foundation, said: “We are delighted that vaccinating all babies against this devastating disease is now within sight.”

Meanwhile, Sue Davie, chief executive of Meningitis Now, said: “This is the news we have been waiting for.”

“To know that babies will be protected against MenB is fantastic and another great step forward in our fight against meningitis,” she added.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.